their diagnosis was revised when systemic symptoms persisted despite corticosteroid therapy. In our experience GCA is an extremely rare cause of scleritis. Patients with scleritis in combination with cephalic symptoms suggestive of GCA, should arouse suspicion of alternate vasculitides. The crossover between symptoms, laboratory results and histopathology can make this a difficult distinction. Thorough systemic review and ongoing monitoring is necessary even after commencement of corticosteroid therapy; hence, referral to rheumatology and immunology is recommended. Early immunosuppressive therapy is often more pressing in systemic vasculitides other than GCA, and can significantly impact on the patient's prognosis.
{"title":"Evaluating the diagnostic utility of evaporative dry eye disease markers","authors":"M. Wang, S. Dean, A. Muntz, J. Craig","doi":"10.1111/ceo.13671","DOIUrl":"https://doi.org/10.1111/ceo.13671","url":null,"abstract":"their diagnosis was revised when systemic symptoms persisted despite corticosteroid therapy. In our experience GCA is an extremely rare cause of scleritis. Patients with scleritis in combination with cephalic symptoms suggestive of GCA, should arouse suspicion of alternate vasculitides. The crossover between symptoms, laboratory results and histopathology can make this a difficult distinction. Thorough systemic review and ongoing monitoring is necessary even after commencement of corticosteroid therapy; hence, referral to rheumatology and immunology is recommended. Early immunosuppressive therapy is often more pressing in systemic vasculitides other than GCA, and can significantly impact on the patient's prognosis.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"146 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86756240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Lock, P. McCluskey, Richard J. Symes, C. Fraser
1. Misra SL, Craig JP, Patel DV, et al. In vivo confocal microscopy of corneal nerves: an ocular biomarker for peripheral and cardiac autonomic neuropathy in type 1 diabetes mellitus. Invest Ophthalmol Vis Sci. 2015;56(9):5060-5065. 2. Misra SL, Kersten HM, Roxburgh RH, Danesh-Meyer HV, McGhee CN. Corneal nerve microstructure in Parkinson's disease. J Clin Neurosci. 2017;39:53-58. 3. Niederer RL, McGhee CN. Clinical in vivo confocal microscopy of the human cornea in health and disease. Prog Retin Eye Res. 2010; 29(1):30-58. 4. Tavakoli M, Kallinikos P, Iqbal A, et al. Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. Diabet Med. 2011;28(10):1261-1267. 5. Yoshida S, Shime H, Funami K, et al. The anti-oxidant ergothioneine augments the immunomodulatory function of TLR agonists by direct action on macrophages. PLoS One. 2017;12(1):e0169360.
{"title":"Giant cell arteritis and scleritis: Does an association exist?","authors":"J. Lock, P. McCluskey, Richard J. Symes, C. Fraser","doi":"10.1111/ceo.13662","DOIUrl":"https://doi.org/10.1111/ceo.13662","url":null,"abstract":"1. Misra SL, Craig JP, Patel DV, et al. In vivo confocal microscopy of corneal nerves: an ocular biomarker for peripheral and cardiac autonomic neuropathy in type 1 diabetes mellitus. Invest Ophthalmol Vis Sci. 2015;56(9):5060-5065. 2. Misra SL, Kersten HM, Roxburgh RH, Danesh-Meyer HV, McGhee CN. Corneal nerve microstructure in Parkinson's disease. J Clin Neurosci. 2017;39:53-58. 3. Niederer RL, McGhee CN. Clinical in vivo confocal microscopy of the human cornea in health and disease. Prog Retin Eye Res. 2010; 29(1):30-58. 4. Tavakoli M, Kallinikos P, Iqbal A, et al. Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. Diabet Med. 2011;28(10):1261-1267. 5. Yoshida S, Shime H, Funami K, et al. The anti-oxidant ergothioneine augments the immunomodulatory function of TLR agonists by direct action on macrophages. PLoS One. 2017;12(1):e0169360.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74260370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A 59-year-old female patient had an intravenous zoledronic acid infusion (5 mg Aclasta; Novartis New Zealand, Auckland, New Zealand) for the treatment of osteoporosis. The next day, she developed a headache, bilateral retro-orbital pain and mild photosensitivity. On the second day, she developed swelling and redness of left eyelids, along with discomfort on eye movements. This was treated as conjunctivitis with chloramphenicol eye drops in the community. It did not resolve and progressed to more swelling with pain on eye movement, and diplopia in all gaze positions other than primary. She denied any history of trauma or sinusitis, and had no recent fever. She has history of trigeminal neuralgia, for which she takes pregabalin. The visual acuities were 6/4.8 in the right eye and 6/6 in the left eye. The intraocular pressures were 22 mmHg in the right eye and 26 mmHg in the left eye. There was marked swelling of left periorbital area, with gross proptosis of 4 mm on Hertel exophthalmometry. The left eye had restricted movement in all gazes (Figure 1). The left upper lid was erythematous with mild tender swelling. On Ishihara colour plates, the patient scored equally in both eyes. There were normal pupillary reflexes, with no relative afferent pupillary defect. Slit lamp examination showed marked conjunctival chemosis, but the anterior chamber and posterior segment were quiet. There were no signs of uveitis or scleritis. Urgent blood tests were done. These showed a normal white blood cell and platelet count, but a mildly elevated Creactive protein of 29 mg/L (reference range < 5). Thyroid stimulating hormone was within the normal range. An orbital computed tomography showed extensive pre-septal oedema and retro-orbital fat stranding. The extraocular muscles were of normal sizes. The paranasal sinuses were normal (Figure 2). The diagnosis of orbital inflammation secondary to zoledronic acid was made. The patient was given intravenous 500 mg methylprednisolone. The signs and symptoms rapidly improved after initial steroid within 24 hours, and the patient was switched to oral prednisone 60 mg daily (1 mg/kg dose). She returned for review 2 weeks after the initial presentation. The left-sided orbital inflammation had completely settled, and there was a full range of eye movement, with no proptosis. The prednisone course was rapidly tapered. Zoledronic acid is a bisphosphonate medication, commonly used for prevention and treatment of osteoporosis and also hypercalcaemia, metastatic bone disease and Paget's disease of bone. Prevalence of osteoporosis in Australia is estimated to be “5.9% for men and 22.8% for women aged 50 years and over, and 12.9% for men and 42.5% for women aged 70 years and over.” Zoledronic acid is considered the first-line prevention and treatment therapy of osteoporosis. Bisphosphonates reduces bone resorption through several mechanisms. It targets osteoclasts, where it reduces recruitment to bone surfaces, inhibits the activity and
{"title":"Zoledronic acid associated orbital inflammation","authors":"Louis S M Han, R. Weatherhead","doi":"10.1111/ceo.13659","DOIUrl":"https://doi.org/10.1111/ceo.13659","url":null,"abstract":"A 59-year-old female patient had an intravenous zoledronic acid infusion (5 mg Aclasta; Novartis New Zealand, Auckland, New Zealand) for the treatment of osteoporosis. The next day, she developed a headache, bilateral retro-orbital pain and mild photosensitivity. On the second day, she developed swelling and redness of left eyelids, along with discomfort on eye movements. This was treated as conjunctivitis with chloramphenicol eye drops in the community. It did not resolve and progressed to more swelling with pain on eye movement, and diplopia in all gaze positions other than primary. She denied any history of trauma or sinusitis, and had no recent fever. She has history of trigeminal neuralgia, for which she takes pregabalin. The visual acuities were 6/4.8 in the right eye and 6/6 in the left eye. The intraocular pressures were 22 mmHg in the right eye and 26 mmHg in the left eye. There was marked swelling of left periorbital area, with gross proptosis of 4 mm on Hertel exophthalmometry. The left eye had restricted movement in all gazes (Figure 1). The left upper lid was erythematous with mild tender swelling. On Ishihara colour plates, the patient scored equally in both eyes. There were normal pupillary reflexes, with no relative afferent pupillary defect. Slit lamp examination showed marked conjunctival chemosis, but the anterior chamber and posterior segment were quiet. There were no signs of uveitis or scleritis. Urgent blood tests were done. These showed a normal white blood cell and platelet count, but a mildly elevated Creactive protein of 29 mg/L (reference range < 5). Thyroid stimulating hormone was within the normal range. An orbital computed tomography showed extensive pre-septal oedema and retro-orbital fat stranding. The extraocular muscles were of normal sizes. The paranasal sinuses were normal (Figure 2). The diagnosis of orbital inflammation secondary to zoledronic acid was made. The patient was given intravenous 500 mg methylprednisolone. The signs and symptoms rapidly improved after initial steroid within 24 hours, and the patient was switched to oral prednisone 60 mg daily (1 mg/kg dose). She returned for review 2 weeks after the initial presentation. The left-sided orbital inflammation had completely settled, and there was a full range of eye movement, with no proptosis. The prednisone course was rapidly tapered. Zoledronic acid is a bisphosphonate medication, commonly used for prevention and treatment of osteoporosis and also hypercalcaemia, metastatic bone disease and Paget's disease of bone. Prevalence of osteoporosis in Australia is estimated to be “5.9% for men and 22.8% for women aged 50 years and over, and 12.9% for men and 42.5% for women aged 70 years and over.” Zoledronic acid is considered the first-line prevention and treatment therapy of osteoporosis. Bisphosphonates reduces bone resorption through several mechanisms. It targets osteoclasts, where it reduces recruitment to bone surfaces, inhibits the activity and","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74949212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vitreoretinal lymphomas are rare ocular cancers, and the subset of primary central nervous system lymphomas that are based in the posterior eye. These tumours are challenging to treat, and today management generally involves a multispecialty team coordinating a treatment protocol that may include intraocular chemotherapy, ocular irradiation, systemic chemotherapy and/or autologous stem cell transplantation. The ophthalmologist has specific responsibility for the intraocular chemotherapy, which is delivered to the eye by intravitreal injection. The most commonly injected drugs are methotrexate—an anti‐metabolite—and rituximab—an anti‐human B cell monoclonal antibody. A range of intraocular chemotherapy treatment schedules have been described in the medical literature, although to date there have been no randomized clinical trials of these schedules. In this article, we review the development and current status of intraocular chemotherapy for vitreoretinal lymphoma.
{"title":"Intraocular chemotherapy for vitreoretinal lymphoma: A review","authors":"Michael Kvopka, Stewart R. Lake, Justine R. Smith","doi":"10.1111/ceo.13668","DOIUrl":"https://doi.org/10.1111/ceo.13668","url":null,"abstract":"Vitreoretinal lymphomas are rare ocular cancers, and the subset of primary central nervous system lymphomas that are based in the posterior eye. These tumours are challenging to treat, and today management generally involves a multispecialty team coordinating a treatment protocol that may include intraocular chemotherapy, ocular irradiation, systemic chemotherapy and/or autologous stem cell transplantation. The ophthalmologist has specific responsibility for the intraocular chemotherapy, which is delivered to the eye by intravitreal injection. The most commonly injected drugs are methotrexate—an anti‐metabolite—and rituximab—an anti‐human B cell monoclonal antibody. A range of intraocular chemotherapy treatment schedules have been described in the medical literature, although to date there have been no randomized clinical trials of these schedules. In this article, we review the development and current status of intraocular chemotherapy for vitreoretinal lymphoma.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"96 1","pages":"240 - 248"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77321723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A healthy 57-year-old man presented with binocular vertical diplopia in 1997. There was no history of headaches, orbital pain or trauma. He adopted a left head tilt and ocular motility examination revealed a right superior oblique palsy with a right hypertropia of five prism dioptres in primary position. The rest of his cranial nerve examination was normal. Contrast-enhanced MRI of the brain and orbits was initially reported as normal. On secondary review, a focal lesion involving the cisternal right fourth nerve (CNIV) was detected. Without contrast, the lesion was isointense with brain parenchyma (Figure 1A); with contrast, the lesion enhanced intensely (Figure 1B). These radiological findings were most in keeping with a CNIV schwannoma. His ocular motility examination remained stable over the next 22 years as did the radiological appearance of the presumed CNIV schwannoma (Figure 2). As his diplopia was successfully managed with prism spectacles, strabismus surgery was not required. Trochlear nerve schwannomas are an unusual cause of isolated superior oblique palsies and are quite rare even in patients with neurofibromatosis type 2. As depicted in this case, CNIV schwannomas may be overlooked if contrast is
{"title":"Trochlear nerve schwannoma: A 22 year follow‐up","authors":"J. Lock, N. Newman, V. Biousse","doi":"10.1111/ceo.13664","DOIUrl":"https://doi.org/10.1111/ceo.13664","url":null,"abstract":"A healthy 57-year-old man presented with binocular vertical diplopia in 1997. There was no history of headaches, orbital pain or trauma. He adopted a left head tilt and ocular motility examination revealed a right superior oblique palsy with a right hypertropia of five prism dioptres in primary position. The rest of his cranial nerve examination was normal. Contrast-enhanced MRI of the brain and orbits was initially reported as normal. On secondary review, a focal lesion involving the cisternal right fourth nerve (CNIV) was detected. Without contrast, the lesion was isointense with brain parenchyma (Figure 1A); with contrast, the lesion enhanced intensely (Figure 1B). These radiological findings were most in keeping with a CNIV schwannoma. His ocular motility examination remained stable over the next 22 years as did the radiological appearance of the presumed CNIV schwannoma (Figure 2). As his diplopia was successfully managed with prism spectacles, strabismus surgery was not required. Trochlear nerve schwannomas are an unusual cause of isolated superior oblique palsies and are quite rare even in patients with neurofibromatosis type 2. As depicted in this case, CNIV schwannomas may be overlooked if contrast is","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79338133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Erdheim-Chester disease (ECD) is a rare, non-Langerhans cell histiocytosis that was first described by Jakob Erdheim and William Chester in 1930. ECD frequently involves multiple systems, such as the skin, bone and central nerve system. The diagnosis of ECD is made by identifying typical histopathological findings in the context of clinical and radiological features, including the infiltration of foamy or lipid-laden histiocytes and positive immunohistochemical staining for CD68. Ocular manifestations have been documented in 25% to 30% of ECD patients, mainly presenting as xanthelasma in the eyelid and infiltration of the orbit. Patients with orbital involvement may complain of exophthalmos, retro-orbital pain or blurring of vision. ECD rarely involves intraocular structures and only less than 10 cases have been reported to date. We hereby described a case of ECD woman with concurrent bilateral choroidal and orbital infiltrates. A 41-year-old woman presented with progressive visual decrease and intermittent pain in her right eye for 2 years. Her ocular history was unremarkable, but she had a history of diabetes insipidus and recurrent pain in her bilateral lower extremities for 5 years. At presentation, her bestcorrected visual acuity was finger count on the right and 20/20 on the left. Intraocular pressure was within the normal range. Hertel exophthalmometer measurements were 16 and 19 mm on the right and left side, respectively. External eye examination revealed sporadic xanthoma in her right eyelids (Figure 1A, arrowhead). Fundoscopy showed bilateral yellowish choroidal mass in the posterior pole with overlying pigmentary clumping (Figure 1B,C).
{"title":"Erdheim‐Chester disease with bilateral choroidal infiltration","authors":"W. Xiao, H. Ye, X. Ji, Huasheng Yang","doi":"10.1111/ceo.13665","DOIUrl":"https://doi.org/10.1111/ceo.13665","url":null,"abstract":"Erdheim-Chester disease (ECD) is a rare, non-Langerhans cell histiocytosis that was first described by Jakob Erdheim and William Chester in 1930. ECD frequently involves multiple systems, such as the skin, bone and central nerve system. The diagnosis of ECD is made by identifying typical histopathological findings in the context of clinical and radiological features, including the infiltration of foamy or lipid-laden histiocytes and positive immunohistochemical staining for CD68. Ocular manifestations have been documented in 25% to 30% of ECD patients, mainly presenting as xanthelasma in the eyelid and infiltration of the orbit. Patients with orbital involvement may complain of exophthalmos, retro-orbital pain or blurring of vision. ECD rarely involves intraocular structures and only less than 10 cases have been reported to date. We hereby described a case of ECD woman with concurrent bilateral choroidal and orbital infiltrates. A 41-year-old woman presented with progressive visual decrease and intermittent pain in her right eye for 2 years. Her ocular history was unremarkable, but she had a history of diabetes insipidus and recurrent pain in her bilateral lower extremities for 5 years. At presentation, her bestcorrected visual acuity was finger count on the right and 20/20 on the left. Intraocular pressure was within the normal range. Hertel exophthalmometer measurements were 16 and 19 mm on the right and left side, respectively. External eye examination revealed sporadic xanthoma in her right eyelids (Figure 1A, arrowhead). Fundoscopy showed bilateral yellowish choroidal mass in the posterior pole with overlying pigmentary clumping (Figure 1B,C).","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84037965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
directed to examine the entire course of this slender nerve. The majority of affected patients are oligosymptomatic with diplopia only and can be observed with serial contrastenhanced MRIs coupled with symptomatic management such as prism glasses or strabismus surgery. It is important to periodically monitor these patients as there is a potential for haemorrhage or growth resulting in brainstem compression. Concerning symptoms include sensory changes, paresis, ataxia and other cranial nerve palsies. Surgical resection is almost always associated with persistence or worsening of superior oblique weakness and carries the risk of stroke, intracranial haemorrhage and damage to surrounding cranial nerves. Therefore, surgery is not recommended as initial treatment of an isolated CNIV schwannoma, but may be necessary if the tumour rapidly enlarges causing mass effect. In slowly progressive cases, radiotherapy may be considered as an alternative treatment modality. In particular, gamma knife stereotactic radiosurgery has recently delivered promising results with small case series reporting reduced tumour volume and improvement of diplopia. This is the longest published follow-up period for a presumed CNIV schwannoma, demonstrating its typical extremely slow-growing nature. Clinical and radiologic observation is favoured over neurosurgical intervention in such cases.
{"title":"Xen gel stent occlusion with iris pigment epithelium","authors":"R. Eagle, R. Razeghinejad","doi":"10.1111/ceo.13658","DOIUrl":"https://doi.org/10.1111/ceo.13658","url":null,"abstract":"directed to examine the entire course of this slender nerve. The majority of affected patients are oligosymptomatic with diplopia only and can be observed with serial contrastenhanced MRIs coupled with symptomatic management such as prism glasses or strabismus surgery. It is important to periodically monitor these patients as there is a potential for haemorrhage or growth resulting in brainstem compression. Concerning symptoms include sensory changes, paresis, ataxia and other cranial nerve palsies. Surgical resection is almost always associated with persistence or worsening of superior oblique weakness and carries the risk of stroke, intracranial haemorrhage and damage to surrounding cranial nerves. Therefore, surgery is not recommended as initial treatment of an isolated CNIV schwannoma, but may be necessary if the tumour rapidly enlarges causing mass effect. In slowly progressive cases, radiotherapy may be considered as an alternative treatment modality. In particular, gamma knife stereotactic radiosurgery has recently delivered promising results with small case series reporting reduced tumour volume and improvement of diplopia. This is the longest published follow-up period for a presumed CNIV schwannoma, demonstrating its typical extremely slow-growing nature. Clinical and radiologic observation is favoured over neurosurgical intervention in such cases.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82434055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Mao, Yuhao Luo, Kun Chen, J. Lao, Lingan Chen, Yirun Shao, Caiyun Zhang, Mingzhai Sun, Lijun Shen
To define a new quantitative grading criterion for retinal haemorrhages in term newborns based on the segmentation results of a deep convolutional neural network.
基于深度卷积神经网络分割结果，建立足月新生儿视网膜出血的定量分级标准。
{"title":"New grading criterion for retinal haemorrhages in term newborns based on deep convolutional neural networks","authors":"J. Mao, Yuhao Luo, Kun Chen, J. Lao, Lingan Chen, Yirun Shao, Caiyun Zhang, Mingzhai Sun, Lijun Shen","doi":"10.1111/ceo.13670","DOIUrl":"https://doi.org/10.1111/ceo.13670","url":null,"abstract":"To define a new quantitative grading criterion for retinal haemorrhages in term newborns based on the segmentation results of a deep convolutional neural network.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"22 1","pages":"220 - 229"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73419841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Hao, A. Pircher, N. Miller, J. Hsieh, L. Remonda, H. Killer
Optic nerve (ON) dysfunction is a common feature of different diseases. The pathophysiology is not yet fully understood.
视神经功能障碍是各种疾病的共同特征。病理生理学尚未完全了解。
{"title":"Cerebrospinal fluid and optic nerve sheath compartment syndrome: A common pathophysiological mechanism in five different cases?","authors":"J. Hao, A. Pircher, N. Miller, J. Hsieh, L. Remonda, H. Killer","doi":"10.1111/ceo.13663","DOIUrl":"https://doi.org/10.1111/ceo.13663","url":null,"abstract":"Optic nerve (ON) dysfunction is a common feature of different diseases. The pathophysiology is not yet fully understood.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"139 1","pages":"212 - 219"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73930325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-25DOI: 10.29328/journal.ijceo.1001027
Sudeep Navule Siddappa, Darshan Shivaura Mahalingu, Rakesha Anjenappa, T. Joy
{"title":"Two different patterns and outcome of neodymium YAG capsulotomy","authors":"Sudeep Navule Siddappa, Darshan Shivaura Mahalingu, Rakesha Anjenappa, T. Joy","doi":"10.29328/journal.ijceo.1001027","DOIUrl":"https://doi.org/10.29328/journal.ijceo.1001027","url":null,"abstract":"","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"64 1","pages":"012-014"},"PeriodicalIF":0.0,"publicationDate":"2020-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76479896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：